Abstract
Purpose: We investigated the influence of sarcopenia on treatment outcomes in elderly patients receiving medical therapy for lower urinary tract symptoms (LUTS).
Methods: We included male patients with LUTS aged ≥75 years who had not changed their medication for 1 year. Current conditions were estimated using IPSS, overactive bladder symptoms score (OABSS), and screening tool for sarcopenia (SARC-F). SARC-F score of ≧4 was defined as sarcopenia.
Results: We included 59 patients in this study, including 16 patients (27.1%) with sarcopenia. IPSS total score, voiding symptom score of IPSS, and IPSS-QOL were significantly higher in the sarcopenia group than the non-sarcopenia group. The non-sarcopenia group had significantly larger PV (40 vs. 20 ml) and higher testosterone levels (497.5 vs. 369 ng/ml) compared with the sarcopenia group. Moderate and severe LUTS (IPSS total ≥8) persisted in 34 patients (57.6%) after medical treatment. Multivariate analysis showed that only SARC-F was a significant factor affecting the IPSS total ≥8 despite medical treatment for 1 year (OR 1.67, 95%CI: 1.13–2.46).
Conclusion: Sarcopenia defined by using SARC-F is a significant factor for unsatisfactory medical treatment of LUTS in elderly men aged ≥75 years.